Private investor clients of Connection Capital, the specialist private client investment business, have invested £6.75m in MatOrtho, to support its international growth and product development.
• MatOrtho’s strong focus on better than competitors’ patient outcomes delivers improved longevity and active quality of life
Founded in 2010, MatOrtho designs, manufactures and commercialises performance leading, orthopaedic implant devices. It is one of the UK’s most innovative orthopaedic device designers. The company has achieved strong growth and has built a truly global presence, supplying implant devices into many of the world’s orthopaedic markets.
MatOrtho’s mission is improving the quality of life of all patients who receive one of its devices. Based in Leatherhead, the company has an international reputation for technical innovation. Its range of advanced knee, hip, and finger replacement procedures consistently deliver clinically proven, best-in-class patient outcomes for implant performance and sustained use with better patient satisfaction.
The investment will enable MatOrtho to accelerate international expansion into new and existing markets and will support research and development as the company continues to develop the next generation of implant technology. The management team will be supported by experienced industry figure, Simon Cartmell, previously CEO of ApaTech, who has joined the board as a Non-Executive.
Michael Coupland, Investment Director at Connection Capital, comments, “We are delighted to be partnering with a company that is delivering improved quality of life for its patients and superior clinical results in the field of orthopaedics. MatOrtho has a strong existing product set and several exciting new products under development, it is well positioned to continue delivering growth and excellent patient outcomes. We are looking forward to working with Mike, Simon and the team as MatOrtho enters the next phase of its growth.”
Mike Tuke, Chairman of MatOrtho says, “MatOrtho and Finsbury before that has always led with game changing implants which have established a leading-edge position in the orthopaedic implants sector, and there is still so much potential to develop innovative new products and increase our market penetration. Having the backing of Connection Capital will be invaluable as we look to accelerate the scaling-up of our business.”
Connection Capital was advised by Gateley (Legal), Smith & Williamson (FDD), Moore Kingston Smith (Tax) and Armstrong (CDD). MatOrtho’s shareholders were advised by Spectrum Corporate Finance (Lead Advisory) and Marriot Harrison (Legal).
About Connection Capital
Connection Capital LLP is a Financial Conduct Authority authorised and regulated, specialist syndicator of investment funds from private professional investors into direct private equity, private debt and commercial property deals, as well as alternative asset funds. It currently has some £320 million of funds under management across a diverse portfolio.
Connection Capital provides a specialist managed service to help professional clients build up their own alternative asset portfolios. Private investors self-select which opportunities they want to take a stake in. Opportunities are identified and negotiated by Connection Capital, which also carries out all due diligence and manages the investment from completion through to exit, on its clients’ behalf.
Press enquiries:
Claire Madden
Managing Partner
Connection Capital
020 3696 4010 or 07764 241476
Russell O’Connor
Headlines for Business 07760 282586